Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy

Lung Cancer

Volumn 79, Issue 2, 2013, Pages 167-172

  Giroux Leprieur, E ^a,b   Antoine, M ^a,c   Vieira, T ^a,c   Duruisseaux, M ^a   Poulot, V ^a   Rabbe, N ^a   Belmont, L ^c   Gounant, V ^c   Lavole A ^c   Milleron, B ^c   Lacave, R ^a   Cadranel, J ^a,c   Wislez, M ^a,c  

^a SORBONNE UNIVERSITÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c HÔPITAL TENON   (France)

Author keywords

ALK translocation; Early progressive disease; EGFR mutations; KRAS mutations; Non small cell lung cancer; Platinum based chemotherapy; Refractory patients; Sarcomatoid carcinoma

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; EXON; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMATOID CARCINOMA; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PACLITAXEL; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84872138283     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.10.010     Document Type: Article

References (55)

1. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
2. Kwak E.L., Bang Y.-J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
3. Socinski M.A., Crowell R., Hensing T.E., Langer C.J., Lilenbaum R., Sandler A.B., et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:277S-289S.
4. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
5. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
6. Depierre A., Chastang C., Quoix E., Lebeau B., Blanchon F., Paillot N., et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994, 5:37-42.
7. Crinò L., Scagliotti G.V., Ricci S., De Marinis F., Rinaldi M., Gridelli C., et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999, 17:3522-3530.
8. Kelly K., Crowley J., Bunn P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210-3218.
9. Rosell R., Gatzemeier U., Betticher D.C., Keppler U., Macha H.N., Pirker R., et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002, 13:1539-1549.
10. Scagliotti G.V., De Marinis F., Rinaldi M., Crinò L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
11. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
12. Smit E.F., van Meerbeeck J.P.A.M., Lianes P., Debruyne C., Legrand C., Schramel F., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003, 21:3909-3917.
13. Gridelli C., Gallo C., Shepherd F.A., Illiano A., Piantedosi F., Robbiati S.F., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:3025-3034.
14. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016-3024.
15. Georgoulias V., Ardavanis A., Agelidou A., Agelidou M., Chandrinos V., Tsaroucha E., et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 2004, 22:2602-2609.
16. Galluzzi L., Senovilla L., Vitale I., Michels J., Martins I., Kepp O., et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31:1869-1883.
17. Munchausen L.L. The chemical and biological effects of cis-dichlorodiammineplatinum (II), an antitumor agent, on DNA. Proc Natl Acad Sci USA 1974, 71:4519-4522.
18. Olaussen K.A., Dunant A., Fouret P., Brambilla E., André F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
19. Joerger M., deJong D., Burylo A., Burgers J.A., Baas P., Huitema A.D.R., et al. Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer 2011, 74:310-317.
20. Lee H.W., Choi Y.-W., Han J.H., Kim J.H., Jung J.H., Jeong S.H., et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer 2009, 65:377-382.
21. Husain A., He G., Venkatraman E.S., Spriggs D.R. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998, 58:1120-1123.
22. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717.
23. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
24. Wislez M., Antoine M., Baudrin L., Poulot V., Neuville A., Pradere M., et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer 2010, 68:185-191.
25. Taron M., Ichinose Y., Rosell R., Mok T., Massuti B., Zamora L., et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005, 11:5878-5885.
26. Jokoji R., Yamasaki T., Minami S., Komuta K., Sakamaki Y., Takeuchi K., et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 2010, 63:1066-1070.
27. Yi E.S., Boland J.M., Maleszewski J.J., Roden A.C., Oliveira A.M., Aubry M.-C., et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011, 6:459-465.
28. World Health Organization classification of tumors. Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon. W.D. Travis, E. Brambilla, H.K. Muller-Herbelink, Harris CC (Eds.).
29. Bae H.-M., Min H.S., Lee S.-H., Kim D.-W., Chung D.H., Lee J.-S., et al. Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer 2007, 58:112-115.
30. Kaira K., Horie Y., Ayabe E., Murakami H., Takahashi T., Tsuya A., et al. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol 2010, 5:460-465.
31. Ito K., Oizumi S., Fukumoto S., Harada M., Ishida T., Fujita Y., et al. Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer 2010, 68:204-210.
32. Pelosi G., Scarpa A., Manzotti M., Veronesi G., Spaggiari L., Fraggetta F., et al. K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. Mod Pathol 2004, 17:538-546.
33. Vieira T., Cazes A., Bonnette P., Zeimoura L., Monnet I., De Cremoux H., et al. Is conventional chemotherapy effective in advanced sarcomatoid lung cancers?. J Clin Oncol 2012, 30. [abstr e18102].
34. Tsao M.-S., Aviel-Ronen S., Ding K., Lau D., Liu N., Sakurada A., et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007, 25:5240-5247.
35. Mascaux C., Iannino N., Martin B., Paesmans M., Berghmans T., Dusart M., et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005, 92:131-139.
36. Mao C., Qiu L.-X., Liao R.-Y., Du F.-B., Ding H., Yang W.-C., et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010, 69:272-278.
37. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
38. Rodenhuis S., Boerrigter L., Top B., Slebos R.J., Mooi W.J., van't Veer L., et al. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 1997, 15:285-291.
39. Beau-Faller M., Degeorges A., Rolland E., Mounawar M., Antoine M., Poulot V., et al. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project-part 1). J Thorac Oncol 2011, 6:1006-1015.
40. Mabry M., Nakagawa T., Nelkin B.D., McDowell E., Gesell M., Eggleston J.C., et al. v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer. Proc Natl Acad Sci USA 1988, 85:6523-6527.
41. Kaufmann S.H., Kalemkerian G.P., Jasti R., Mabry M. Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin. Biochem Pharmacol 1995, 50:1987-1993.
42. Isonishi S., Hom D.K., Thiebaut F.B., Mann S.C., Andrews P.A., Basu A., et al. Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res 1991, 51:5903-5909.
43. Tsai C.M., Chang K.T., Perng R.P., Mitsudomi T., Chen M.H., Kadoyama C., et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993, 85:897-901.
44. Mok T.S., Wu Y.-L., Thongprasert S., Yang C.-H., Chu D.-T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
45. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
46. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
47. Zhou C., Wu Y.-L., Chen G., Feng J., Liu X.-Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
48. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
49. Koh Y., Kim D.-W., Kim T.M., Lee S.-H., Jeon Y.K., Chung D.H., et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol 2011, 6:905-912.
50. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
51. Modok S., Mellor H.R., Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 2006, 6:350-354.
52. Italiano A., Cortot A.B., Ilie M., Martel-Planche G., Fabas T., Pop D., et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 2009, 125:2479-2482.
53. Lee S., Kim Y., Sun J.-M., Choi Y.L., Kim J.G., Shim Y.-M., et al. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. J Cancer Res Clin Oncol 2011, 137:1203-1211.
54. Pelosi G., Gasparini P., Cavazza A., Rossi G., Graziano P., Barbareschi M., et al. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer 2012, 77:507-514.
55. Blaukovitsch M., Halbwedl I., Kothmaier H., Gogg-Kammerer M., Popper H.H. Sarcomatoid carcinomas of the lung-are these histogenetically heterogeneous tumors?. Virchows Arch 2006, 449:455-461.